ReFOLD Bio discovers gene editing targets for protein misfolding diseases that affect hundreds of millions of patients worldwide. ReFOLD identifies novel refolding edits that restore protein function without correcting the original mutation. This approach unlocks a blue ocean: patients carrying mutations that no existing gene therapy can address. Targets are validated directly in patient-derived organoids, producing assets with substantially higher translational confidence than industry standard.

River BioMedics offers new human cardiac 3D models for target validation during drug discovery. Our 3D models are scalable to high-throughput and provide clinically relevant cardiac readouts for reliable drug efficacy validation.

Saturn offers a personalized solution for Pelvic Organ Prolapse by providing a pessary with a perfect fit and optimal support for each patient's complex, unique anatomy.

SAVE develops a safer, child-friendly formulation of sirolimus for patients with vascular anomalies, aiming to eliminate side effects and improve long-term treatment adherence. Led by Radboudumc experts, SAVE seeks to transform care and quality of life for patients across Europe.

With Fybrix, we offer a synthetic, customizable and animal-free 3D cell culture material that uniquely mimics the native cell environment, in contrast to other synthetic materials that have been introduced in the market.

CRISPR-Cas has revolutionized the field of gene editing and will also disrupt the field of molecular diagnostics. CRISPR diagnostics (CRISPR-Dx), combined with a pre-amplification step, are faster and easier than (q)PCR whilst obtaining results of the same quality.

Development and clinical application of molecular assays for the early detection of cancer

Sella Therapies is a clinical-stage medical device company developing a novel therapy for chronic pain relief that targets the body’s internal neuropeptide system.

Sencilia has developed a first-of-its-kind flow sensing device to reduce medication errors due to flow instabilities in intravenous infusions in neonates.

SeraNovo’s proprietary formulation platform radically increases bioavailability and allows products to reach the market significantly quicker, at a lower cost.